Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the tr...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-07-01
|
Series: | HIV/AIDS: Research and Palliative Care |
Subjects: | |
Online Access: | https://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIV |
_version_ | 1818691844365615104 |
---|---|
author | Fernandez C van Halsema CL |
author_facet | Fernandez C van Halsema CL |
author_sort | Fernandez C |
collection | DOAJ |
description | Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors |
first_indexed | 2024-12-17T12:48:21Z |
format | Article |
id | doaj.art-a09d2af3a9054c7f880cb8e75d206c4b |
institution | Directory Open Access Journal |
issn | 1179-1373 |
language | English |
last_indexed | 2024-12-17T12:48:21Z |
publishDate | 2019-07-01 |
publisher | Dove Medical Press |
record_format | Article |
series | HIV/AIDS: Research and Palliative Care |
spelling | doaj.art-a09d2af3a9054c7f880cb8e75d206c4b2022-12-21T21:47:40ZengDove Medical PressHIV/AIDS: Research and Palliative Care1179-13732019-07-01Volume 1117919247555Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potentialFernandez Cvan Halsema CLCristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase inhibitorshttps://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIVantiretroviral therapyintegrase inhibitorsnon-nucleoside reverse transcriptase inhibitors |
spellingShingle | Fernandez C van Halsema CL Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential HIV/AIDS: Research and Palliative Care antiretroviral therapy integrase inhibitors non-nucleoside reverse transcriptase inhibitors |
title | Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential |
title_full | Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential |
title_fullStr | Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential |
title_full_unstemmed | Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential |
title_short | Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential |
title_sort | evaluating cabotegravir rilpivirine long acting injectable in the treatment of hiv infection emerging data and therapeutic potential |
topic | antiretroviral therapy integrase inhibitors non-nucleoside reverse transcriptase inhibitors |
url | https://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIV |
work_keys_str_mv | AT fernandezc evaluatingcabotegravirrilpivirinelongactinginjectableinthetreatmentofhivinfectionemergingdataandtherapeuticpotential AT vanhalsemacl evaluatingcabotegravirrilpivirinelongactinginjectableinthetreatmentofhivinfectionemergingdataandtherapeuticpotential |